Exploring biomarkers in mild traumatic brain injury diagnosis

1. Current challenges in diagnosing mild traumatic brain injury
2. Overview of biomarkers relevant to brain injury
3. Emerging technologies for biomarker detection
4. Clinical applications and diagnostic accuracy
5. Future directions and research recommendations

Diagnosing mild traumatic brain injury (mTBI) remains a significant clinical challenge due to the often subtle and non-specific nature of symptoms. Unlike severe brain injuries that present with clear structural abnormalities on imaging, mTBI may not produce detectable changes on conventional CT or MRI scans. This lack of visible damage underscores the necessity for more sensitive diagnostic tools, particularly those leveraging neurodiagnostics such as the use of biomarkers.

One of the primary difficulties clinicians face is that symptoms of mTBI — such as headache, dizziness, confusion, and fatigue — overlap with a range of other conditions, including psychological stress and non-neurological injuries. Moreover, these symptoms can vary widely in duration and intensity, making it difficult to distinguish an mTBI from other transient complaints. Without a reliable, objective measure, such as a specific biomarker, diagnosis often relies heavily on patient self-report and clinician judgement, which can be subjective and prone to bias.

The timing of diagnosis adds another layer of complexity. Many individuals delay seeking medical care after a head injury, particularly if symptoms appear mild at first. However, early identification of mTBI is crucial for preventing secondary complications and for guiding appropriate activity modifications, especially in populations at higher risk such as athletes and military personnel. This delayed presentation can make it challenging to obtain accurate clinical histories and to correlate symptoms with the injury event.

Inconsistencies in diagnostic criteria across healthcare systems and institutions also hinder accurate diagnosis. Various clinical tools and checklists are used to assess the presence and severity of mTBI, but these are not standardised globally. The lack of uniform guidelines can result in underdiagnosis or misdiagnosis, potentially leading to inadequate treatment and prolonged recovery times for patients.

There is increasing interest in the development of blood tests as part of neurodiagnostics to address these challenges. The idea is to identify biomarkers — measurable biological indicators — that are released into the bloodstream following a brain injury. However, even though promising candidates have been identified, such as glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), the translation of these biomarkers into routine clinical practice is still limited. Questions remain regarding their sensitivity, specificity, and how well they can differentiate mTBI from other conditions or anticipate outcomes.

The diagnostic landscape for mTBI is characterised by a reliance on subjective assessments, limited effectiveness of imaging techniques for subtle injuries, and a pressing need for objective, accessible, and reliable diagnostic tools. Biomarkers offer a potential solution to many of these challenges, but further research and validation are essential to integrate them into standard practice effectively.

Overview of biomarkers relevant to brain injury

Biomarkers play a vital role in the effort to improve diagnostic protocols for mild traumatic brain injury (mTBI), particularly in situations where traditional neuroimaging techniques show limited sensitivity. These biological indicators can reflect a wide spectrum of neuropathological processes triggered by brain injury—ranging from neuronal damage and glial response to axonal injury and blood-brain barrier disruption. Their presence and concentration in bodily fluids, especially blood and cerebrospinal fluid, make them attractive candidates for rapid and non-invasive assessment via neurodiagnostics.

Among the most studied biomarkers for brain injury are glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1). GFAP, an intermediate filament protein expressed in astrocytes, serves as a marker of glial injury and has demonstrated robustness in differentiating mTBI from non-brain-related trauma. UCH-L1, found in neurons, becomes elevated in serum following neuronal cell body damage. These two biomarkers have shown sufficient reliability to be FDA-approved in the United States for use in evaluating mild brain injury within 12 hours of head trauma, particularly as an aid in determining the necessity of a CT scan.

Another promising biomarker is S100B, a calcium-binding protein released primarily by astrocytes. Elevated serum S100B concentrations have been correlated with brain tissue damage and are particularly useful in ruling out significant intracranial bleeding in a subset of patients. However, its specificity can be limited as S100B levels may also rise due to extracerebral injuries or intense physical exercise, making interpretation in certain clinical contexts more challenging.

Neurofilament light chain (NfL), a structural axonal protein, has also generated significant interest. Its levels in blood increase following axonal damage, and it has been linked to long-term outcomes in brain injury, including cognitive decline and persistent post-concussive symptoms. Unlike some acute-phase biomarkers, NfL may remain elevated for weeks, offering insights into injury progression and recovery rather than immediate diagnosis alone.

Inflammation-related biomarkers such as interleukins (e.g., IL-6, IL-10) and tumour necrosis factor alpha (TNF-α) provide additional avenues for characterising the neuroinflammatory component of mTBI. These proteins may not be exclusive to brain-specific insults, but in combination with other markers, they can contribute to a more nuanced picture of the pathophysiological processes involved.

MicroRNAs—small, non-coding RNA molecules involved in gene regulation—are emerging as novel biomarkers with the potential to reflect broad cellular responses to injury. Several microRNAs have shown altered expression profiles following mTBI and may be incorporated into future blood tests, supporting both diagnosis and prognosis.

Despite the encouraging evidence, the application of these biomarkers in routine clinical settings still faces important limitations. Variability in assay platforms, absence of universally accepted threshold values, and differences in timing of sample collection can affect the reproducibility and interpretation of results. Ongoing studies aim to validate combinations of biomarkers—rather than relying on a single indicator—to enhance diagnostic sensitivity and specificity for mTBI.

Incorporating biomarker analysis into early neurodiagnostics holds great promise for transforming the management of mTBI. These biological tools, particularly when used in conjunction with clinical assessment and imaging, have the potential to bring much-needed objectivity to a condition that has long been diagnosed through subjective means.

Emerging technologies for biomarker detection

Technological advancements are revolutionising the way biomarkers for mild traumatic brain injury (mTBI) are detected and quantified, propelling neurodiagnostics into a new era. Traditional methods of biomarker analysis, often reliant on enzyme-linked immunosorbent assays (ELISAs), have been instrumental in initial discoveries but face limitations in terms of sensitivity, speed, and their capacity for multiplexing. Recent developments aim to overcome these hurdles, prioritising point-of-care utility and the ability to detect biomarker panels in the early stages following injury.

One of the most promising innovations is the emergence of immunoassay platforms with enhanced sensitivity, such as single molecule array (Simoa) technology. Simoa enables detection of extremely low concentrations of brain-derived biomarkers, such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), in blood samples, even when these levels are below the detection thresholds of conventional assays. This ultra-sensitive capability is crucial for capturing subtle biological changes shortly after a mild head trauma, thereby facilitating earlier and more accurate diagnosis of mTBI.

Microfluidic devices represent another major breakthrough, offering compact, portable systems capable of performing complex blood tests with minimal reagent use and short turnaround times. These chip-based platforms can integrate multiple stages, including sample preparation, biomarker detection, and signal analysis, within a single device. Their miniaturised format and ease of use support bedside applications in emergency departments, sports arenas, and military field settings, where rapid decisions are vital.

Mass spectrometry-based proteomics is also gaining traction in mTBI research, particularly for the discovery of novel biomarkers. These high-throughput techniques analyse the protein composition of biofluids in exquisite detail, enabling identification of candidate markers that might otherwise remain undetected. Though not yet viable for routine diagnostics due to cost and complexity, these approaches provide critical insights that inform the development of more targeted and practical blood-based tests for clinical application.

Integration of machine learning algorithms with biomarker detection technologies is opening new avenues for personalising diagnosis. Leveraging artificial intelligence to interpret complex datasets from multiplex biomarker panels allows for more accurate classification of injury severity and prediction of recovery trajectories. These algorithms can take into account temporal patterns in biomarker fluctuations, patient-specific demographics, and clinical observations, providing a comprehensive neurodiagnostic profile that enhances clinical decision-making.

Wearable biosensors represent an emerging frontier, particularly those designed to monitor physiological data relevant to mTBI in near real-time. While still largely in the research phase, some prototypes aim to detect molecular biomarkers through non-invasive means, such as sweat or interstitial fluid analysis. These devices offer future potential for continuous monitoring of individuals at high risk of brain injury, such as athletes or military personnel, potentially signalling the occurrence of an mTBI even before symptoms fully manifest.

Digital health platforms, including mobile applications and cloud-based data systems, are increasingly being integrated with biomarker technologies to streamline the collection, analysis, and storage of diagnostic data. These platforms facilitate remote monitoring and can automate alerts for clinically significant biomarker patterns, helping clinicians respond promptly. Data harmonisation between devices and healthcare systems is a key area of development to ensure these technologies can be implemented at scale.

Together, these emerging technologies are poised to significantly enhance the role of biomarkers in diagnosing mTBI. By improving the speed, accessibility, and accuracy of neurodiagnostics, they promise to reduce reliance on subjective symptom reporting and traditional imaging—leading to more informed clinical decisions and ultimately better outcomes for patients affected by this often-overlooked form of brain injury.

Clinical applications and diagnostic accuracy

The integration of biomarkers into clinical settings is progressively transforming the landscape of mild traumatic brain injury (mTBI) diagnosis. As research yields a growing number of promising blood tests, these neurodiagnostics are increasingly being examined for their accuracy, reliability, and overall utility in real-world medical environments. These applications range from acute emergency care to long-term monitoring, offering new possibilities for objective, evidence-based decision-making.

In emergency departments, rapid blood tests for mTBI biomarkers such as UCH-L1 and GFAP are emerging as adjunct tools to reduce unnecessary neuroimaging. Clinical studies have shown that when used within a specific time window following injury—typically within 12 hours—these biomarkers can accurately identify patients at low risk for intracranial abnormalities, thus helping clinicians determine who may safely forego a CT scan. This approach enhances patient safety by minimising radiation exposure and reduces healthcare costs without compromising diagnostic sensitivity.

Beyond acute triage, biomarker analysis also shows promise for stratifying patients based on the severity and anticipated trajectory of neurological recovery. For example, elevated levels of neurofilament light chain (NfL) have been linked to more persistent post-concussive symptoms, flagging individuals who may benefit from closer follow-up or early intervention. Used in conjunction with clinical assessment, these biomarkers enable more tailored care pathways, potentially improving prognosis and reducing the likelihood of chronic complications.

In sports medicine, particularly in contact sports like rugby or football, blood-based neurodiagnostics are showing utility in the sideline assessment of athletes following suspected concussion. Emerging point-of-care platforms can deliver biomarker results in a rapid timeframe, aiding in real-time decisions on whether a player should be removed from play. This objective approach supplements existing concussion protocols, which rely heavily on subjective symptom checklists that can be influenced by player underreporting or observer bias.

Similarly, in military settings, where mTBI is a common and sometimes under-reported injury, biomarker-based diagnostics are being considered as deployment-ready tools. Field-compatible blood tests offer the potential to identify service members affected by blast injuries or head trauma, even in the absence of overt clinical symptoms. By improving early detection and documentation, these tools could play a vital role in treatment planning and long-term care for personnel affected by invisible injuries.

Importantly, the diagnostic accuracy of biomarker tests is highly dependent on timing, specificity, and cut-off thresholds, which vary across different platforms. Clinical validation studies have begun to define optimal time windows for sample collection and interpretive ranges for individual markers. Combining multiple biomarkers into panels further strengthens diagnostic performance by capturing a broader spectrum of neurophysiological responses, such as glial, neuronal, and axonal damage. When used in tandem, GFAP and UCH-L1, for instance, show improved sensitivity and specificity compared to either marker alone.

The implementation of these blood tests into routine clinical workflows also depends on logistical considerations such as turnaround time, cost-effectiveness, and ease of use. Advances in laboratory automation and point-of-care devices are helping to alleviate such concerns, making biomarker testing more realistic for a variety of clinical environments. In addition, ongoing digital integration with electronic health records enables clinicians to access historical biomarker profiles, supporting longitudinal assessments across multiple visits.

Despite these promising developments, certain limitations persist. Variability in biomarker expression between individuals, the influence of comorbidities, and cross-reactivity with non-neurological injuries can all impact the interpretive clarity of test results. Therefore, clinical use of biomarkers is best applied as a complement to—rather than a replacement for—traditional diagnostic tools. Multimodal evaluation, incorporating medical history, symptom inventories, imaging, and biomarker levels, yields the most informative and accurate assessment for patients with suspected mTBI.

Ultimately, applying neurodiagnostics in the form of biomarker-guided blood tests represents a critical step towards standardising and objectifying the diagnosis of mTBI. Continued clinical trials and real-world implementation studies will further define their role across diverse patient populations and health care systems, helping to bridge the gap between research innovation and everyday medical practice.

Future directions and research recommendations

Research into biomarkers for mild traumatic brain injury (mTBI) is rapidly evolving, yet several crucial avenues remain to be explored in order to translate these findings into consistent and reliable clinical practice. One key direction for future work is the establishment of uniform protocols for biomarker sampling and analysis. At present, discrepancies in blood test methodologies and biomarker threshold values across studies limit the comparability of findings, and in turn, hinder their clinical applicability. A concerted effort toward the standardisation of neurodiagnostic procedures is essential, particularly regarding sample timing post-injury, assay selection, and data interpretation benchmarks.

Additionally, larger, multi-centre clinical trials are needed to validate existing biomarker candidates under real-world conditions. Such studies should account for a broader diversity of patient populations, including variables such as age, sex, pre-existing health conditions, and types of injury. This broader scope would contribute to a more accurate understanding of how biomarkers behave across different scenarios and could influence diagnostic thresholds tailored to specific subgroups. Furthermore, longitudinal studies that track biomarker levels over weeks and months following injury are vital to evaluate their prognostic utility and to detect delayed complications of mTBI.

Another promising research area lies in the development of multimodal diagnostic models that combine biomarkers with imaging findings, clinical symptomatology, and neurocognitive assessments. Current evidence suggests that no single biomarker offers comprehensive coverage of the complex pathophysiological changes associated with brain injury. By integrating data from multiple sources—including glial, neuronal, axonal, and inflammatory biomarkers—alongside neurodiagnostics derived from imaging and psychological evaluation, it may be possible to design a more holistic and sensitive diagnostic framework for mTBI.

Emerging ‘omics’ technologies, such as proteomics, transcriptomics, and metabolomics, are anticipated to yield new classes of biomarkers with improved specificity and sensitivity. These high-throughput techniques, although currently more common in research settings, have the potential to uncover novel molecular pathways involved in mTBI, leading to both better diagnostic targets and possible therapeutic interventions. These discoveries will require careful validation but could significantly enhance the biomarker repertoire available for blood tests in clinical practice.

Critically, the future of biomarker implementation also depends on refining point-of-care technologies to make blood-based neurodiagnostics more practical in diverse clinical contexts. Efforts should focus on reducing the cost and complexity of these tools while improving their portability and scalability. Research into minimally invasive or non-invasive sampling methods—such as from saliva, breath, or wearable biosensors—may further support broader adoption, especially in environments where traditional phlebotomy is impractical.

Public and private research funding must be sustained and expanded to support the cross-disciplinary collaborations required for biomarker development. This includes partnerships between neuroscientists, clinicians, bioengineers, and software developers to innovate around both the biological and technological challenges inherent in diagnosing mTBI. Establishing centralised data repositories for biomarker research could also accelerate progress by enabling large-scale data sharing, meta-analyses, and machine learning applications designed to refine diagnostic algorithms.

Policy-oriented research will be increasingly important to assess the health-economic implications of incorporating biomarker-guided blood tests into standard care pathways. Evaluating cost-effectiveness, patient outcomes, and health system impacts will inform guidelines and influence regulatory decisions. These considerations are particularly relevant as new products approach commercial readiness and seek approval for widespread clinical use.

Ethical and regulatory frameworks must also evolve to match the rapid pace of biomarker and neurodiagnostic innovation. As tests become increasingly sensitive, determining how to manage borderline or incidental findings will be a growing challenge. Establishing clear clinical pathways based on biomarker levels—especially in asymptomatic individuals or during routine screening—will be essential to avoid overdiagnosis or unnecessary intervention.

Realising the full potential of biomarkers in mTBI diagnosis depends on a strategic blend of rigorous research, technological development, cross-sector collaboration, and clinical validation. These efforts, though multifaceted, hold the promise of significantly advancing the precision and efficacy of neurodiagnostics for one of the most common yet elusive types of brain injury.